AKB-9778: Phase II started

By WIR Staff | Feb 17, 2014 | 8:00 AM GMT

Aerpio began a double-blind, placebo-controlled, U.S. Phase II trial to compare subcutaneous 15 mg AKB-9778 twice

Read the full 167 word article

How to gain access

Continue reading with a
two-week free trial.